Lisa Gill and Elizabeth Anderson questioned Cencora regarding growth moderation and RCA integration in August 2025.
2 reports, 1 independent
Updated Aug 13
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lisa Gill and Elizabeth Anderson questioned Cencora regarding growth moderation and RCA integration in August 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cencora
US drug wholesale company company
-
Lisa Gill
researcher
Nothing else this week.
-
Elizabeth Anderson
researcher (ORCID 0000-0002-6210-8653)
Nothing else this week.
Coverage
Newest first; wire copies grouped- StockStoryThe 5 Most Interesting Analyst Questions From Cencora’s Q2 Earnings Call Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market re
- StockStoryCOR Q2 Deep Dive: Specialty Growth, International Headwinds, and Guidance Update Healthcare distributor Cencora (NYSE:COR) announced better-than-expected revenue in Q2 CY2025, with sales up 8.7% year